Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2012 Oct;64(10):1447-61.
doi: 10.1002/acr.21773.

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis

Dinesh Khanna  1 , Puja P Khanna, John D Fitzgerald, Manjit K Singh, Sangmee Bae, Tuhina Neogi, Michael H Pillinger, Joan Merill, Susan Lee, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, Fernando Perez-Ruiz, Will Taylor, Frédéric Lioté, Hyon Choi, Jasvinder A Singh, Nicola Dalbeth, Sanford Kaplan, Vandana Niyyar, Danielle Jones, Steven A Yarows, Blake Roessler, Gail Kerr, Charles King, Gerald Levy, Daniel E Furst, N Lawrence Edwards, Brian Mandell, H Ralph Schumacher, Mark Robbins, Neil Wenger, Robert Terkeltaub; American College of Rheumatology
Affiliations
Practice Guideline

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis

Dinesh Khanna et al. Arthritis Care Res (Hoboken). 2012 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Author conflict of interests are provided directly from the American College of Rheumatology and detailed separately.

Figures

Figure 1
Figure 1. Case scenarios for defining acute gouty arthritis attack features
These case scenarios were generated by the CEP, and therapeutic decision making options for these scenarios were voted on by the TFP.
Figure 2
Figure 2. Overview of management of an acute gout attack
This algorithm summarizes the recommendations by the TFP on the overall approach to management of an acute attack of gouty arthritis, with further details, as expanded in other figures and tables, referenced in the figure, and discussed in the text.
Figure 3
Figure 3. Recommendations for the individual pharmacologic monotherapy options for an acute gouty arthritis attack
The Figure is separated into distinct parts that schematize use of the first line therapy options (NSAIDs, corticosteroids, colchicine), and specific recommendations by the TFP.
Figure 4
Figure 4. Acute gouty arthritis attack management in the nil per os (NPO) patient
The Figure schematizes options for management of acute gout in the patient unable to take oral anti-inflammatory medications, and specific recommendations by the TFP on decision making in this setting.
Figure 5
Figure 5. Pharmacologic anti-inflammatory prophylaxis of gout attacks, and its relationship to pharmacologic ULT
The Figure provides an algorithm for use of anti-nflammatory prophylaxis agents to prevent acute gout attacks. The schematic highlights specific recommendations by the TFP on decision making on the initiation, options, and duration of prophylaxis relative to pharmacologic ULT therapy, relative to achievement of the treatment objectives of ULT.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Khanna D, FitzGerald JD, Khanna PP, Bae S, Singh M, Neogi N, et al. 2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res. 2012 (submitted) - PMC - PubMed
    1. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301–4. - PubMed
    1. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17:609–14. - PubMed
    1. Brook RA, Forsythe A, Smeeding JE, Edwards NL. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010;26:2813–21. - PubMed
    1. Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14:10–5. - PubMed

Publication types

MeSH terms